WHO updates antiretroviral dosing guidance for newborns, infants and children

Broad summary: WHO released updated guidance for dosing antiretroviral medicines in newborns, infants and children. The update is technical, but its public-health impact is practical: safer, clearer dosing can help health workers treat children according to age, weight and clinical situation. What happened: The guidance sets out harmonized weight-band dosing schedules and updates recommendations for key medicines including dolutegravir and abacavir/lamivudine. What is confirmed: WHO says the guidance covers pediatric formulations, preterm infants, prevention versus treatment dosing and adjustments when a child is also treated for tuberculosis. What remains uncertain: Adoption timelines, local procurement and availability of pediatric formulations will depend on each country. Editorial note: This is health information, not individual medical advice. Treatment decisions belong to qualified clinicians.